Trial Profile

A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clofazimine (Primary) ; Rifapentine (Primary) ; Ethambutol; Isoniazid; Pyrazinamide; Pyridoxine; Rifampicin
Indications Pulmonary tuberculosis
Focus Adverse reactions; Therapeutic Use
Acronyms CLO-FAST; The CLO-FAST Study

01 Jan 2026 Primary endpoint (Proportion of participants across study arms experiencing any Grade 3 or higher adverse event (AE) that is at least a one grade increase from baseline) has not been met, based on results published in The Lancet Infectious Diseases.
01 Jan 2026 Primary endpoint (Time to stable culture conversion in liquid media) has been met, based on results published in The Lancet Infectious Diseases.
01 Jan 2026 Results published in The Lancet Infectious Diseases.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com